X Genomics Inc . (NASDAQ:TXG) reported its Q4 2024 earnings, revealing a larger-than-expected loss per share and a decline in revenue compared to the previous year. The company posted an EPS of -$0.40 ...

Gentian Diagnostics reported a robust financial performance for Q4 2024, achieving record quarterly sales of NOK 42.6 million, marking a 14% year-over-year increase. The company's stock surged by 7.58 ...